Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ/III Studies to Investigate the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Hepatocellular Carcinoma

NCT05408221 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT05408221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05408221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ/III Studies to Investigate the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Hepatocellular Carcinoma
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 2/3
Overall status
Unknown status
Start date
November 11, 2022
Completion date
August 1, 2026
Enrollment
576 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma